Mathew Pletcher

SVP, Research at Astellas Gene Therapies

Mathew Pletcher, Ph.D. is Senior Vice President, Research at Audentes Therapeutics. He is responsible for advancing the company’s pipeline from discovery through to IND-enabling preclinical development.

Prior to Audentes in July 2020, Mr. Pletcher worked at Roche Pharma where he was Head of Rare Diseases Research and Early Development, and prior to that, Head of Discovery. Previously, he served as Acting Chief Scientific Officer at Autism Speaks and earlier as Vice President, Head of Genomic Sciences. He also spent eight years working in Pfizer’s Rare Diseases Research Unit in various scientific roles of increasing responsibility including Director, Rare Diseases Research Unit.

Mr. Pletcher also founded and leads a non-profit foundation, Fund for Sight, supporting research and resources for families and children impacted by the genetic disease his daughter inherited called Leber Congenital Amaurosis. He holds a Bachelor of Science in Biology from Duquesne University and a Ph.D. in Human Genetics form Johns Hopkins School of Medicine.

Timeline

  • SVP, Research

    Current role

View in org chart